Quantcast

Latest Ribavirin Stories

2011-04-04 05:30:00

ABBOTT PARK, Ill., and WATERTOWN, Mass., April 4, 2011 /PRNewswire/ -- Abbott (NYSE: ABT) and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C (HCV) infection.

2011-04-04 00:00:27

Higher virologic response rates achieved at 4 weeks (RVR)* and maintained through 12 weeks of treatment (cEVR)** across all genotypes studied Princeton, NJ (PRWEB) April 2, 2011 – Bristol-Myers Squibb Company (NYSE: BMY) today announced results from the Phase IIb EMERGE clinical trial, in which treatment with the investigational compound PEG-Interferon lambda and ribavirin achieved higher rates of rapid virologic response (RVR) in genotypes 1, 2, 3, and 4, and complete early...

2011-04-03 21:53:40

Data presented at the International Liver CongressTM highlight the fact that new novel antiviral compounds for the treatment of hepatitis C virus (HCV) must be prescribed and monitored by experts and specialists to ensure resistance is minimized.

2011-04-02 01:00:00

RIDGEFIELD, Conn., April 2, 2011 /PRNewswire/ -- Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most challenging genotype to treat.

2011-04-01 09:00:00

BERLIN and RIDGEFIELD, Conn., April 1, 2011 /PRNewswire/ -- New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver (EASL) demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 (GT1) hepatitis C virus (HCV), the most challenging genotype of HCV to treat.

2011-04-01 00:00:00

HUDDINGE, Sweden, April 1, 2011 /PRNewswire-FirstCall/ -- - Results Show Potent Antiviral Efficacy of Once Daily 150 mg TMC435 in Hepatitis C Patients Who Have Failed Earlier Treatment, Especially in Prior Null Responders, and Excellent Safety and Tolerability Medivir AB (OMX: MVIR), the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner, Tibotec has presented the results of a planned Week 24 interim analysis of the...

2011-04-01 00:01:02

Adverse event profile of regimen containing BMS-790052 was consistent with that of treatment with PEG-Interferon alfa and ribavirin alone Princeton, NJ (PRWEB) March 31, 2011 Bristol-Myers Squibb Company(NYSE: BMY) today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral (DAA) BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin (RBV), achieved sustained virologic response 12...

2011-03-31 22:47:57

New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C (HCV).

2011-03-31 01:55:37

A three-drug cocktail can eliminate the hepatitis C virus in patients far more effectively than the current two-drug regimen.

2011-03-30 05:45:00

PRINCETON, N.J., March 30, 2011 /PRNewswire/ -- Pharmasset, Inc. (Nasdaq: VRUS) announced today that screening has begun in a Phase 2b study of PSI-7977, a nucleotide analog polymerase inhibitor for the treatment of chronic hepatitis C (HCV).


Latest Ribavirin Reference Libraries

0_b3d737125981cbedce0bb0c8511e6b65
2011-02-17 15:14:03

Lassa fever, first described in 1969 in Lassa, is an acute viral hemorrhagic fever. Clinical cases were known a decade before this but were not associated with this viral pathogen. It is endemic in West African countries and causes approximately 5,000 deaths. The Natal Multimammate Mouse is the primary animal host. The rodent is a source of protein but the virus is usually transmitted by the contact with the feces and urine of animals accessing grain stores in residences. The lassa virus...

More Articles (1 articles) »
Word of the Day
ultimo
  • In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.
  • In the month which preceded the present; in the last month, as distinguished from the current or present month and all others.
The word 'ultimo' comes from the Latin phrase 'ultimo mense', 'in the last month'.
Related